National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00695838
First received: June 10, 2008
Last updated: August 4, 2009
Last verified: August 2009
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | June 10, 2008 | ||||
| Last Updated Date | August 4, 2009 | ||||
| Start Date ICMJE | January 2008 | ||||
| Primary Completion Date | Not Provided | ||||
| Current Primary Outcome Measures ICMJE |
Waist circumference [ Time Frame: Once ] | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00695838 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | National Survey on Gastroesophageal Reflux Disease (GERD) Patients | ||||
| Official Title ICMJE | Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice | ||||
| Brief Summary | The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms . |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | First three consecutive patients with GERD symptoms seen by GP |
||||
| Condition ICMJE | GERD | ||||
| Intervention ICMJE | Not Provided | ||||
| Study Group/Cohort (s) | 1 | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 5084 | ||||
| Completion Date | December 2008 | ||||
| Primary Completion Date | Not Provided | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | France | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00695838 | ||||
| Other Study ID Numbers ICMJE | NIS-GFR-DUM-2007/3 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals | ||||
| Study Sponsor ICMJE | AstraZeneca | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | AstraZeneca | ||||
| Verification Date | August 2009 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||